Table 3.
Selected trials of teclistamab in multiple myeloma (MM).
| Trial ID (References) | Drugs | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| NCT04557098 [95,96,97,98] | Tec | I/II | 244 | First-in-Human, Open-Label, Dose Escalation Study of Teclistamab in Subjects with RRMM (MajesTEC-1) |
| NCT03145181 [99] | Tec iv vs. Tec sc | I | 282 | First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody in Subjects with RRMM (MajesTEC-1) |
| NCT04722146 [100,101] | Tec in various combinations with antimyeloma agents | Ib | 140 | A Multi-arm Study of Teclistamab with Other Anticancer Therapies in Participants with MM (MajesTEC-2) |
| NCT05083169 [102] | (Dara + Tec) vs. (Dara + Pom + Bort + Dex) | III | 560 | Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with RRMM (MajesTEC-3) |
| NCT05243797 [103] | (Tec +/− Len) vs. Len | III | 1500 | Teclistamab in Combination with Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants with NDMM as Maintenance Therapy Following Autologous Stem Cell Transplantation—MajesTEC-4 |
| NCT05552222 [104] | Tec + Dara + Len vs. Dara + Len +Dex | III | 1060 | Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with NDMM Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (MajesTEC-7) |
| NCT05572515 | Tec vs. (Pom + Bort + Dex or Carf + Dex) | III | 590 | Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with RRMM Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9) |
| NCT04586426 | Tec + Tal + Dara | I/II | 164 | Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with RRMM (RedirecTT-1) |
| NCT04108195 [105,106] | (Dara + Tec +/− Pom) vs. (Dara + Tal +/− Pom) | I | 295 | Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with MM (TRIMM-2) |
| NCT05338775 | Tec + Tal + “PD-1 inhibitor” | Ib | 152 | Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with RRMM (TRIMM-3) |
Bort = bortezomib; Carf = carfilzomib; Dara = daratumumab; Dex = dexamethasone; Len = lenalidomide; MM = multiple myeloma; NDMM = newly diagnosed MM; Pom = pomalidomide; RRMM = relapsed and/or refractory MM; Tal = talquetamab; Tec = teclistamab.